scholarly journals Whole body vibration training improves leg blood flow and adiposity in patients with type 2 diabetes mellitus

2013 ◽  
Vol 113 (9) ◽  
pp. 2245-2252 ◽  
Author(s):  
Borja Sañudo ◽  
Rosa Alfonso-Rosa ◽  
Borja del Pozo-Cruz ◽  
Jesus del Pozo-Cruz ◽  
Delfín Galiano ◽  
...  
2019 ◽  
Vol 43 (7) ◽  
pp. 524-529.e2 ◽  
Author(s):  
Mansueto Gomes-Neto ◽  
Danúbia da Cunha de Sá-Caputo ◽  
Laisa Liane Paineiras-Domingos ◽  
Andrea Araujo Brandão ◽  
Mario F. Neves ◽  
...  

2009 ◽  
Vol 106 (2) ◽  
pp. 566-570 ◽  
Author(s):  
Lynn A. Sokolnicki ◽  
Nicholas A. Strom ◽  
Shelly K. Roberts ◽  
Shirley A. Kingsley-Berg ◽  
Ananda Basu ◽  
...  

Individuals with type 2 diabetes mellitus (T2DM) often exhibit microvascular dysfunction that may contribute to impaired thermoregulation, but potential mechanisms remain unclear. Our goals were to quantify skin blood flow responses and nitric oxide-mediated vasodilation during body heating in individuals with T2DM compared with nondiabetic control subjects of similar age. We measured skin blood flow (laser-Doppler flowmetry) in conjunction with intradermal microdialysis of NG-nitro-l-arginine methyl ester (l-NAME; nitric oxide synthase inhibitor) or vehicle during 45–60 min of whole body heating (WBH) in 10 individuals with T2DM and 14 control subjects. In six individuals from each group, we also measured forearm blood flow (FBF) by venous occlusion plethysmography on the contralateral forearm. FBF responses showed diminished absolute cutaneous vasodilation during WBH in the T2DM group ( PANOVA < 0.01; peak FBF in control 13.1 ± 1.7 vs. T2DM 9.0 ± 1.6 ml·100 ml−1·min−1). However, the relative contribution of nitric oxide to the cutaneous vasodilator response (expressed as % of maximal cutaneous vascular conductance) was not different between groups ( P > 0.05). We conclude that cutaneous vasodilator responses to WBH are decreased in individuals with T2DM, but the contribution of nitric oxide to this smaller vasodilation is similar between T2DM and control individuals. This decrease in cutaneous vasodilation is likely an important contributor to impaired thermoregulation in T2DM.


SpringerPlus ◽  
2015 ◽  
Vol 4 (1) ◽  
Author(s):  
Hongyu Yin ◽  
Henrik O. Berdel ◽  
David Moore ◽  
Franklin Davis ◽  
Jun Liu ◽  
...  

2006 ◽  
Vol 100 (2) ◽  
pp. 637-641 ◽  
Author(s):  
Diane E. Wick ◽  
Shelly K. Roberts ◽  
Ananda Basu ◽  
Paola Sandroni ◽  
Robert D. Fealey ◽  
...  

Epidemiological evidence suggests decreased heat tolerance in patients with Type 2 diabetes mellitus (T2DM), but it is not known whether the mechanisms involved in thermoregulatory control of skin blood flow are altered in these patients. We tested the hypothesis that individuals with T2DM have a delayed internal temperature threshold for active cutaneous vasodilation during whole body heating compared with healthy control subjects. We measured skin blood flow using laser-Doppler flowmetry (LDF), internal temperature (Tor) via sublingual thermocouple, and mean arterial pressure via Finometer at baseline and during whole body heating in 9 T2DM patients and 10 control subjects of similar age, height, and weight. At one LDF site, sympathetic noradrenergic neurotransmission was blocked by local pretreatment with bretylium tosylate (BT) to isolate the cutaneous active vasodilator system. Whole body heating was conducted using a water-perfused suit. There were no differences in preheating Tor between groups ( P > 0.10). Patients with T2DM exhibited an increased internal temperature threshold for the onset of vasodilation at both untreated and BT-treated sites. At BT-treated sites, Tor thresholds were 36.28 ± 0.07°C in controls and 36.55 ± 0.05°C in T2DM patients ( P < 0.05), indicating delayed onset of active vasodilation in patients. Sensitivity of vasodilation was variable in both groups, with no consistent difference between groups ( P > 0.05). We conclude that altered control of active cutaneous vasodilation may contribute to impaired thermoregulation in patients with T2DM.


1995 ◽  
Vol 4 (2) ◽  
pp. 80-84 ◽  
Author(s):  
Karre I. Birkeland ◽  
Kristian F. Hanssen ◽  
Einar Stranden ◽  
Jan A. Falch ◽  
Stein Vaaler

2020 ◽  
Vol 2020 ◽  
pp. 1-16 ◽  
Author(s):  
Elena V Tchetina ◽  
Galina A Markova ◽  
Eugeniya P Sharapova

Osteoarthritis (OA) and type 2 diabetes mellitus (T2D) are two of the most widespread chronic diseases. OA and T2D have common epidemiologic traits, are considered heterogenic multifactorial pathologies that develop through the interaction of genetic and environmental factors, and have common risk factors. In addition, both of these diseases often manifest in a single patient. Despite differences in clinical manifestations, both diseases are characterized by disturbances in cellular metabolism and by an insulin-resistant state primarily associated with the production and utilization of energy. However, currently, the primary cause of OA development and progression is not clear. In addition, although OA is manifested as a joint disease, evidence has accumulated that it affects the whole body. As pathological insulin resistance is viewed as a driving force of T2D development, now, we present evidence that the molecular and cellular metabolic disturbances associated with OA are linked to an insulin-resistant state similar to T2D. Moreover, the alterations in cellular energy requirements associated with insulin resistance could affect many metabolic changes in the body that eventually result in pathology and could serve as a unified mechanism that also functions in many metabolic diseases. However, these issues have not been comprehensively described. Therefore, here, we discuss the basic molecular mechanisms underlying the pathological processes associated with the development of insulin resistance; the major inducers, regulators, and metabolic consequences of insulin resistance; and instruments for controlling insulin resistance as a new approach to therapy.


Sign in / Sign up

Export Citation Format

Share Document